Milestone Scientific Surges Again

  • Milestone Scientific has a platform technology for the safe delivery of injections, with one application already commercialized and another one (the CompuFlo) close.
  • The health and cost benefits of the CompuFlo are clear, and there is an obvious and large market with 11 million epidurals per year in the US alone.
  • There has been a delay in the commercialization process, and the company’s dental business is suffering, hence the extreme share price volatility.
  • With a new financing and restrictions on dental practices easing, better times might lay ahead, but this is only for the risk-tolerant investor.

Source: Milestone Scientific Surges Again (NYSEMKT:MLSS) | Seeking Alpha